CDC treats first mon­key­pox pa­tient with SIGA's small­pox an­tivi­ral via ex­pand­ed ac­cess

The CDC said Fri­day that one mon­key­pox pa­tient in the US so far has been treat­ed with SIGA Tech­nolo­gies’ tecovir­i­mat, known com­mer­cial­ly as TPOXX, which is an an­tivi­ral agent from the strate­gic na­tion­al stock­pile with an­ti-or­thopoxvirus ac­tiv­i­ty.

The an­tivi­ral is on­ly cur­rent­ly li­censed to treat small­pox, so the FDA and com­pa­ny made it avail­able to CDC un­der an ex­pand­ed ac­cess IND.

CDC al­so said it re­leased small­pox vac­cines — Emer­gent’s ACAM2000 and Bavar­i­an Nordic’s Jyn­neos — to those at high-risk of ex­po­sure to mon­key­pox, ei­ther through con­tact with some­one who has it, or cer­tain in­ter­me­di­ate risk ex­po­sures, such as be­ing with­in ≤6 feet of an un­masked pa­tient for ≥3 hours with­out wear­ing, at a min­i­mum, a sur­gi­cal mask.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER